Atlas Trials

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

Clinical trial NCT02549196 · COMPLETED

Trial details

NCT number
NCT02549196
Sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Dementia of Alzheimer's Type
Start date
2015-10-07
Primary completion
2017-09-28
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.